system
biolog
put
togeth
rather
take
apart
integr
rather
reduct
requir
develop
way
think
integr
rigor
reductionist
programm
differ
mean
chang
philosophi
full
sens
term
lthough
tradit
antivir
drugdiscoveri
approach
yield
notabl
success
recent
year
propens
virus
develop
drug
resist
result
suboptim
treatment
outcom
owe
poor
therapi
complianc
patient
continu
provid
commerci
medic
incent
develop
innov
effect
therapeut
increas
adopt
highthroughput
technolog
possibl
get
detail
view
virushost
interact
come
focu
inform
omic
experi
begin
popul
databas
grand
scale
abil
stitch
togeth
vast
amount
data
therebi
investig
model
understand
biolog
process
system
level
crucial
pursuit
new
therapeut
target
articl
provid
snapshot
realiz
potenti
applic
system
biolog
antivir
research
use
specif
case
studi
discuss
associ
shortcom
need
address
advanc
technolog
fullest
potenti
past
year
sever
major
pharmaceut
compani
either
depriorit
discontinu
antivir
vaccin
program
smaller
less
riskavers
biotech
compani
enter
antivir
arena
payoff
lucr
antivir
vaccin
market
gross
global
sale
billion
sever
factor
contribut
appar
resurg
antivir
vaccin
marketplac
includ
emerg
spread
viral
diseas
worldwid
particularli
hivaid
recent
sever
acut
respiratori
syndrom
sar
avian
influenza
outbreak
grow
perceiv
actual
threat
bioterror
recent
approv
vaccin
certain
strain
human
papilloma
viru
hpv
associ
high
rate
cervic
cancer
turn
creat
demand
technolog
advanc
molecular
biolog
develop
afford
rapid
viral
assay
spur
growth
molecular
diagnost
industri
much
global
public
health
demand
antivir
vaccin
product
grow
fact
antivir
therapeut
remain
extrem
challeng
goal
inevit
industri
need
implement
fundament
innov
chang
antivir
drugdiscoveri
process
success
opportun
ampl
ever
technolog
advanc
wholegenom
sequenc
profil
usher
era
largescal
highthroughput
biolog
field
virolog
specif
us
nation
center
biotechnolog
inform
ncbi
bethesda
md
genbank
contain
evergrow
list
complet
sequenc
viral
genom
time
although
approxim
us
food
drug
administr
fda
approv
antivir
drug
market
mani
either
target
viral
protein
variat
drug
furthermor
larg
part
human
genom
remain
poorli
annot
understood
highlight
limit
knowledg
host
biolog
key
question
remain
virus
encod
rel
gene
constantli
outmaneuv
host
like
us
encod
gene
believ
integr
systemwid
approach
fig
includ
transcriptom
metabolom
proteom
highthroughput
techniqu
combin
mathemat
model
comput
biolog
hold
great
potenti
understand
biolog
complex
virushost
interact
translat
prevent
person
medicin
combat
viral
infect
hostori
antivir
discoveri
paradigm
mani
current
antivir
drug
direct
viral
encod
enzym
essenti
viral
replic
despit
remark
success
viralinhibitor
drug
control
viral
infect
diseas
progress
exampl
combin
revers
transcriptas
proteas
inhibitor
aid
suffer
seriou
drawback
particular
limit
success
erad
chronic
viral
infect
one
drawback
approach
mani
drug
use
treat
specif
viral
speci
even
subtyp
design
target
inhibit
specif
viral
enzym
narrow
spectrum
action
reduc
potenti
toxic
associ
target
nonspecif
enzym
also
greatli
limit
usag
market
potenti
drug
furthermor
mani
medic
import
virus
influenza
virus
hepat
c
viru
hcv
inher
capac
rapidli
mutat
becom
resist
even
potent
drug
lowfidel
replic
mode
reason
singl
antiretrovir
drug
target
longer
recommend
clinic
use
necessit
use
combin
therapi
although
combin
therapi
effect
suppress
viral
replic
regimen
expens
associ
greater
advers
side
effect
result
poor
patient
adher
altern
search
new
gener
antivir
drug
made
difficult
fact
mani
clinic
import
virus
small
rna
virus
genom
usual
encod
dozen
gene
less
hand
product
gene
enzym
known
bind
pocket
small
molecul
thu
consid
druggabl
pharmaceut
industri
reason
mention
unreason
argu
treat
viral
infect
stimul
manipul
subvert
host
antivir
respons
target
cellular
enzym
cofactor
requir
viral
life
cycl
could
provid
advantag
tradit
viralinhibitor
approach
host
cell
offer
wealth
proven
druggabl
target
cell
surfac
receptor
protein
kinas
nuclear
receptor
proteasom
moreov
antivir
drug
target
cellular
pathway
may
less
suscept
emerg
drug
resist
human
gene
encod
target
cellular
protein
less
like
mutat
respons
therapi
inde
experiment
evid
support
notion
provid
util
pharmacolog
inhibitor
cyclindepend
kinas
cdk
fig
block
replic
herp
simplex
viru
hsv
fact
attempt
isol
resist
strain
virus
unsuccess
cell
cultur
system
importantli
sever
cdk
inhibitor
develop
potenti
anticanc
drug
thu
far
major
toxic
observ
human
clinic
trial
thu
combin
drug
target
common
cellular
pathway
requir
life
cycl
differ
virus
antivir
andor
immunomodul
may
abl
develop
regimen
capabl
treat
multipl
viral
diseas
target
host
cell
factor
antivir
therapi
view
major
risk
industri
sound
genet
evid
specif
genom
chang
well
toler
mammal
yet
offer
strong
protect
viral
infect
exampl
natur
occur
homozyg
mutat
human
ccmotif
receptor
protein
confer
resist
hiv
infect
pfizer
new
york
ny
selzentrycelsentri
maraviroc
exampl
recent
approv
drug
target
antihiv
therapi
like
potenti
resist
mechan
also
exploit
mammal
furthermor
recent
initi
romark
laboratori
tampa
fl
phase
clinic
trial
nitazoxanid
treat
chronic
hepat
c
unit
state
repres
first
new
class
smallmolecul
drug
call
thiazolid
target
cell
signal
pathway
use
viral
replic
also
noteworthi
current
standard
treatment
hcv
combin
pegyl
interferon
ifn
ribavirin
iron
nonspecif
antivir
drug
target
cellular
factor
ifn
activ
multipl
intracellular
pathway
establish
intracellular
antivir
immun
ribavirin
act
least
part
deplet
intracellular
pool
guanin
nucleotid
inhibit
cellular
inosin
monophosph
dehydrogenas
tolllik
receptor
tlr
agonist
imiquimod
immun
modifi
rapidli
induc
ifn
antivir
effector
molecul
approv
treatment
genit
wart
caus
hsv
inde
consider
develop
host
respons
modul
antivir
treatment
exampl
system
administr
oxoguanosin
select
agonist
patient
result
dosedepend
induct
immunolog
biomark
statist
signific
antivir
effect
rel
mild
side
effect
addit
ligand
adenin
reduc
hcv
rna
level
cell
carri
hcv
replicon
least
part
induct
type
ifn
stimul
besid
agonist
agonist
cpgcontain
oligonucleotidein
combin
pegyl
ifn
andor
ribavirin
also
figur
conceptu
illustr
variou
system
approach
appli
studi
virushost
interact
mean
understand
diseas
biolog
model
system
chemic
genet
perturb
would
provid
insight
repertoir
novel
target
therapeut
intervent
strategi
host
factor
biomark
discoveri
viral
determin
diagnost
c
e
n
ta
r
induc
earli
respons
chronic
hcvinfect
patient
prior
relaps
respons
critic
contend
hostori
pharmacolog
approach
caus
side
effect
target
viral
target
although
antivir
drug
type
immun
safeti
concernsa
demonstr
recent
halt
sever
trial
promis
antivir
candid
pathway
vital
fundament
cellular
process
necessari
modul
rather
ablat
enzym
involv
minim
potenti
sever
side
effect
success
identifi
small
molecul
treat
variou
chronic
human
disord
manag
advers
effect
ca
nt
viral
infect
paracelsu
aptli
note
thing
poison
noth
without
poison
dose
make
thing
poison
although
appear
major
larg
pharmaceut
compani
yet
visibl
embrac
potenti
system
biolog
approach
grow
number
virologist
academia
embark
quest
refin
appli
tool
system
biolog
understand
fulli
interact
viru
host
box
deciph
mechan
diseas
requir
deep
knowledg
multipl
concurr
signaltransduct
pathway
oper
deregul
inescap
intricaci
signal
pathway
often
highli
interconnect
tempor
spatial
regul
dissect
systemlevel
approach
coupl
compendium
analysi
system
biolog
potenti
discov
novel
prohost
therapeut
target
provid
robust
overview
host
cellular
machineri
respons
interact
viru
kind
analys
offer
inroad
toward
develop
innov
therapeut
act
concert
host
defens
mechan
sever
notabl
case
studi
support
use
full
systemsscal
analys
ration
antivir
drug
develop
categor
three
gener
area
viral
pathogenesi
function
identif
novel
viral
host
gene
drug
target
predict
antivir
drug
respons
patient
stratif
increas
evid
function
genom
experi
pattern
cellular
respons
varieti
viral
infect
may
reflect
pathogen
properti
virus
contend
dissect
critic
often
subtli
differ
cellular
pathway
eventu
unveil
opportun
manipul
host
immun
respons
fight
viral
infect
control
pathogenesi
primari
object
research
laboratori
mgk
determin
viral
cellular
factor
respons
increas
virul
pandem
viral
strain
particularli
influenza
viru
found
mice
infect
viru
contain
eight
gene
pandem
viru
show
dramat
activ
proinflammatori
celldeath
pathway
hour
infectiona
phenomenon
continu
unab
anim
death
day
ref
contrast
situat
influenza
virus
contain
subset
gene
induc
less
mark
host
immun
respons
measur
gene
express
level
use
microarray
produc
less
sever
diseas
patholog
kill
infect
mice
slowli
studi
repres
first
comprehens
analysi
global
host
respons
induc
influenza
viru
anim
model
specif
illustr
genom
approach
lead
us
figur
biolog
network
select
gene
induc
twofold
p
lung
mice
infect
recombin
influenza
viru
compar
uninfect
control
use
depict
activ
celldeath
respons
infect
macaqu
monkey
use
extens
model
wide
varieti
human
diseas
aid
research
particular
also
taken
challeng
develop
genom
resourc
focus
macaqu
speci
effort
result
sequenc
rhesu
macaqu
genom
develop
oligonucleotid
microarray
contain
uniqu
macaqu
sequenc
studi
suggest
lethal
associ
viru
culmin
cooper
interact
viral
gene
result
onetwo
blow
host
attenu
express
specif
innat
immun
respons
gene
includ
certain
gene
associ
type
ifn
respons
follow
sever
persist
inflammatori
celldeath
respons
may
contribut
sever
immunopatholog
inde
data
suggest
best
treatment
virul
viru
would
combin
antivir
compound
exist
antiinflammatori
drug
work
laboratori
mgk
also
address
wide
rang
viral
pathogen
includ
hcv
ebola
viru
west
nile
viru
sarsassoci
coronaviru
hsv
hiv
longterm
goal
assembl
massiv
databas
describ
host
respons
multipl
viral
agent
multipl
model
system
believ
care
dissect
databas
reveal
secret
necessari
devis
effect
antivir
strategi
host
cell
process
microarray
analysi
measur
gene
express
transcript
level
also
begun
incorpor
complementari
approach
proteom
bioinformat
appli
system
biolog
studi
viral
infect
virusassoci
diseas
collect
clinic
data
human
anim
hope
integr
genom
proteom
clinic
dataset
enhanc
abil
understand
underli
mechan
host
defens
respons
viral
infect
import
dissect
impact
viral
infect
host
pathway
vice
versa
also
becom
appar
function
virogenom
rapidli
evolv
exemplifi
ongo
work
laboratori
idek
colleagu
combin
gene
express
profil
known
proteinprotein
interact
unravel
transcript
regulatori
network
govern
latenc
earli
reactiv
phase
anoth
studi
uetz
et
al
recent
use
dock
algorithm
infer
virushost
protein
interact
map
two
herpesviruseskaposi
sarcomaassoci
herpesviru
kshv
varicella
zoster
viru
vzv
basi
experiment
data
gener
yeast
twohybrid
screen
compar
proteom
studi
suggest
viral
host
interactom
possess
distinct
network
topolog
also
interplay
may
lead
emerg
new
system
properti
repres
specif
featur
viral
pathogenesi
research
institut
system
biolog
isb
seattl
wa
nice
summar
properti
biolog
system
make
attract
systemslevel
explorationemerg
properti
robust
modular
emerg
trait
whole
greater
sum
part
robust
characterist
resili
fluctuat
immedi
environ
result
redund
control
mechan
modular
phenomenon
explain
cluster
part
function
structur
entiti
said
certain
featur
virushost
interact
make
particularli
interest
global
investig
case
point
emerg
properti
discoveri
aberr
innat
immun
respons
macaqu
lethal
infect
influenza
viru
robust
hiv
latenc
rapid
lowfidel
turnov
wide
recogn
factor
continu
infect
resist
modular
predict
varicella
zoster
virushuman
kshvhuman
network
seen
uetz
work
figur
function
relationship
activ
cell
death
respons
influenza
viru
infect
biolog
network
select
gene
induc
least
twofold
p
mous
lung
compar
uninfect
control
diagram
show
direct
solid
line
indirect
dash
line
interact
report
cell
death
blue
shade
immun
responserel
gene
yellow
shade
gray
denot
gene
multipl
andor
undefin
biolog
function
biolog
network
analysi
perform
use
ingenu
system
redwood
citi
ca
ingenu
pathway
analysi
program
show
statist
signific
assess
use
fisher
exact
test
use
calcul
p
valu
determin
probabl
biolog
function
andor
diseas
assign
dataset
due
chanc
alon
time
abl
combin
experiment
comput
studi
model
viral
infect
process
chan
et
al
demonstr
import
step
toward
goal
redesign
genom
bacteriophag
host
escherichia
coli
incorpor
paramet
describ
host
phage
nucleic
acid
polymeras
host
protein
synthesi
machineri
well
tempor
express
phage
gene
result
suggest
intrigu
notion
primari
limit
growth
number
ribosom
wherea
much
polymeras
actual
caus
excess
transcript
phage
earli
gene
divers
ribosom
away
make
capsid
protein
lategen
transcript
avail
protein
interact
network
largescal
virushost
interact
data
boost
knowledg
function
mani
still
poorli
character
viral
protein
well
larg
number
remain
unknown
gene
host
pathway
lead
detail
understand
viral
pathogenesi
provid
potenti
new
target
interf
either
viru
host
key
point
infect
instanc
recent
unbias
global
proteom
analysi
led
identif
previous
unknown
immunomodulatori
function
pathogen
protein
kshv
bioinformat
gene
detect
system
capabl
detect
group
novel
hiv
regulatori
gene
repress
express
host
gene
bind
untransl
region
also
report
inde
similar
viral
regulatori
gene
known
microrna
identifi
sever
dna
virus
includ
herpesvirus
polyomaviru
laboratori
mgk
recent
publish
first
host
proteom
analysi
cell
studi
analyz
express
level
protein
cell
line
infect
lai
strain
protein
assess
use
liquid
chromatographymass
spectrometri
coupl
stabl
isotop
label
accur
mass
time
tag
approach
analysi
reveal
protein
chang
abund
peak
viru
product
hour
infect
pathway
analysi
reveal
differenti
express
protein
concentr
select
biolog
pathway
ubiquitinconjug
enzym
carrier
protein
nucleocytoplasm
transport
cdk
cell
cycl
progress
pyruv
dehydrogenas
citrat
cycl
pathway
moreov
chang
observ
abund
protein
known
interact
viral
protein
proteom
analysi
captur
chang
host
protein
milieu
time
robust
viru
product
depict
chang
cellular
process
may
contribut
viru
replic
host
protein
may
inde
prove
futur
target
antivir
therapi
medic
import
rna
virus
hiv
tend
encod
swiss
armi
knife
protein
capabl
perform
one
function
differ
stage
viral
life
cycl
often
accomplish
hijack
host
enzym
carri
posttransl
modif
protein
phosphoryl
produc
version
viral
protein
differ
biolog
function
understand
process
time
viral
gene
express
protein
posttransl
modif
role
viral
life
cycl
reveal
mechan
viru
replic
andor
pathogenesi
discuss
may
also
identifi
host
cellular
target
protein
kinas
suitabl
therapeut
intervent
exampl
microarray
studi
reveal
elev
level
prostaglandin
requir
effici
replic
human
cytomegaloviru
hcmv
fibroblast
lead
experiment
demonstr
inhibitor
block
accumul
immediateearli
viral
mrna
protein
cell
cultur
suggest
drug
target
cellular
pathway
could
use
treat
hcmv
infect
similarli
function
genom
studi
reveal
ckit
one
consist
kshvinduc
gene
inhibit
ckit
activ
pharmacolog
inhibitor
ckit
signal
revers
kshvinduc
morpholog
transform
cell
cultur
lck
heterogen
nuclear
ribonucleoprotein
hnrnp
upregul
latent
hivinfect
cell
interestingli
lck
signal
event
link
rna
process
translat
via
lck
kinasemedi
phosphoryl
hnrnp
k
may
regul
hiv
transcript
translat
andor
rna
process
suggest
lck
could
promis
drug
target
hiv
latenc
system
biolog
approach
use
cellbas
screen
identifi
drug
candid
host
target
unsuspect
role
recent
proof
concept
strategi
provid
sakamoto
et
al
use
hcv
replicon
system
research
screen
identifi
smallmolecul
hcv
replic
inhibitor
work
prevent
de
novo
synthesi
sphingolipid
inhibit
host
serin
palmitoyltransferas
disrupt
assembl
hcv
nonstructur
protein
lipid
raft
coupl
genomewid
rna
interfer
screen
system
cell
biolog
screen
could
power
approach
identifi
host
factor
requir
viral
replic
pathogenesi
inde
pelkman
innov
sequenc
technolog
particularli
rapid
highthroughput
pyrosequenc
platform
continu
transform
largescal
biolog
illustr
point
ncbi
genbank
contain
overwhelm
complet
sequenc
uniqu
viral
genom
complet
viral
genom
influenza
viru
sequenc
date
along
genom
goal
person
human
genom
project
necessit
advanc
bioinformat
comput
biolog
carri
wholegenom
comparison
intrahost
interhost
strain
well
hosthost
variat
stimul
commentari
holm
ask
thoughtprovok
question
use
genom
data
understand
evolutionari
interact
concurr
circul
pathogen
host
influenc
diseas
etiolog
exampl
rise
opportunist
pathogenrel
infect
hiv
pandem
host
immun
shape
pathogen
divers
respons
infect
exampl
interact
among
four
dengu
serotyp
furthermor
intrahost
interhost
genet
variabl
import
understand
crossspeci
transmiss
emerg
avian
flu
viru
prime
exampl
field
viral
metagenom
viral
diagnost
therefor
pois
rapid
expans
beyond
burgeon
express
profil
dataset
databas
ncbi
geo
mgk
laboratori
gener
array
dataset
past
seven
year
use
commerci
intern
develop
microarray
platform
dataset
provid
clue
host
determin
infect
usher
era
person
virom
along
line
braganeto
colleagu
provid
illumin
discuss
overwhelm
scale
potenti
immunom
aim
uncov
host
immunolog
respons
antigen
develop
set
stage
systemslevel
analys
develop
better
safer
person
treatment
prevent
modal
demonstr
power
use
kinomewid
rna
interfer
rnai
screen
identifi
host
factor
facilit
infecti
entri
vesicular
stomat
viru
simian
viru
interestingli
found
limit
overlap
kinas
regul
entri
two
virus
suggest
virus
har
differ
host
endocyt
machineri
gain
entri
may
offer
select
approach
target
variou
class
virus
taken
togeth
studi
suggest
system
biolog
potenti
uncov
common
viral
theme
base
share
molecular
signatur
network
may
vulner
disrupt
could
lead
develop
broadli
applic
control
strategi
virus
highli
attract
nich
applic
highthroughput
genom
antivir
drug
vaccin
develop
lie
survey
host
viral
variat
identifi
sourc
virul
suscept
box
advent
highthroughput
genotyp
platform
also
made
possibl
carri
unbias
genomewid
associ
studi
uncov
mediumpenetr
risk
allel
illustr
exampl
recent
report
first
wholegenom
associ
studi
identifi
host
determin
infect
research
found
three
polymorph
explain
nearli
variat
viral
load
among
individu
could
lead
improv
therapi
new
target
vaccin
develop
pharmacogenom
initi
enhanc
higherdens
platform
snp
array
detect
singlenucleotid
polymorph
snp
singl
experi
detail
associ
genotyp
individu
respons
infect
treatment
allow
physician
limit
use
drug
may
danger
subset
popul
group
individu
benefit
treatment
kind
studi
alreadi
underway
therapi
hiv
hcv
hpv
hepat
b
viru
enter
unpreced
time
inform
product
via
highthroughput
technolog
comput
advanc
tip
iceberg
prospect
system
biolog
studi
virushost
interact
excit
ever
recent
advanc
noninvas
technolog
imag
fundament
process
exampl
transcript
regul
signaltransduct
cascad
proteinprotein
interact
cell
traffick
live
cell
anim
model
exampl
neglect
area
investig
replic
site
positivestrand
rna
virus
hcv
sar
coronaviru
replic
genom
intracellular
membran
compart
simultan
avoid
minim
delay
doublestrand
rnainduc
host
antivir
respons
activ
protein
kinas
rnaactiv
pkr
rnase
l
rna
interfer
mani
intracellular
compart
also
harbor
host
defens
sensor
endosom
vesicl
antivir
effector
rigi
retinoicacidinduc
gene
perk
protein
kinas
pkr
like
er
kinas
mitochondria
endoplasm
reticulum
respect
despit
major
battleground
hostviru
conflict
exact
site
viral
rna
synthesi
compon
host
viral
factor
organ
function
intracellular
membran
compart
poorli
understood
integr
ultrastructur
liveanim
imag
technolog
function
genom
comput
analysi
possibl
character
featur
membraneassoci
rna
replic
complex
virus
gener
systemsbas
model
facilit
understand
gener
principl
mechan
positivestrand
rna
viru
replic
well
virus
evas
immun
system
field
antivir
therapi
combin
therapi
becom
norm
system
biolog
approach
allow
one
formul
multicompon
drug
achiev
optim
efficaci
reduc
mechanismbas
toxic
undoubtedli
signific
impact
antivir
drug
discoveri
develop
vaccin
develop
anoth
promis
approach
develop
newli
emerg
peptid
microarray
use
antigen
peptid
fix
probe
serum
antibodi
target
identifi
antibodi
reactiv
pattern
potenti
valuabl
clinic
biomark
involv
viru
infect
concept
highlight
studi
examin
antibodi
respons
simian
immunodefici
viru
hiv
use
array
display
peptid
deriv
viral
amino
acid
sequenc
studi
found
reduct
repertoir
antibodi
respons
associ
develop
aid
correl
efficaci
vaccin
candid
host
immun
respons
may
gain
better
molecular
understand
thu
becom
better
abl
predict
efficaci
vaccin
candid
nt
promis
largescal
biolog
provid
us
yet
raft
new
antivir
therapeut
current
system
biolog
approach
suffer
sever
experiment
comput
drawback
highthroughput
approach
sensit
way
sampl
collect
handl
varieti
factor
rna
protein
degrad
presenc
contamin
tissu
influenc
gene
express
proteom
analysi
although
lot
time
effort
gone
amelior
kind
problem
gener
reproduc
result
genom
experi
variabl
across
platform
laboratori
remain
issu
attempt
integr
dataset
differ
sourc
challeng
need
integr
multipl
level
biolog
data
individu
experi
also
data
differ
group
assay
translat
highthroughput
data
digest
result
easili
interpret
broader
audienc
includ
clinician
government
regul
scientist
requir
close
collabor
among
virologist
pathologist
clinician
biologist
statistician
bioinformatician
collabor
consortia
largescal
network
scienc
partnership
industri
academia
ensur
high
qualiti
sampl
data
gener
process
analysi
well
eas
data
access
interpret
